Retirement Systems of Alabama Has $67.81 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Retirement Systems of Alabama cut its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.7% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 129,163 shares of the biopharmaceutical company’s stock after selling 2,219 shares during the period. Retirement Systems of Alabama owned about 0.12% of Regeneron Pharmaceuticals worth $67,811,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of REGN. Activest Wealth Management increased its holdings in shares of Regeneron Pharmaceuticals by 110.5% during the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 21 shares in the last quarter. Costello Asset Management INC acquired a new stake in Regeneron Pharmaceuticals in the first quarter valued at $27,000. Saudi Central Bank acquired a new stake in Regeneron Pharmaceuticals in the first quarter valued at $27,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in Regeneron Pharmaceuticals in the second quarter valued at $31,000. Finally, Colonial Trust Advisors acquired a new stake in Regeneron Pharmaceuticals in the first quarter valued at $32,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently weighed in on the company. Rothschild & Co Redburn assumed coverage on Regeneron Pharmaceuticals in a report on Thursday, August 14th. They issued a “buy” rating and a $890.00 price objective for the company. UBS Group restated a “neutral” rating on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Morgan Stanley decreased their price objective on Regeneron Pharmaceuticals from $761.00 to $756.00 and set an “overweight” rating for the company in a report on Friday, October 10th. Truist Financial decreased their price objective on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating for the company in a report on Monday, August 11th. Finally, Guggenheim increased their price objective on Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the company a “buy” rating in a report on Wednesday. Three analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $813.78.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $652.91 on Thursday. The company has a current ratio of 4.82, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $69.20 billion, a P/E ratio of 15.63, a price-to-earnings-growth ratio of 2.04 and a beta of 0.31. The firm’s fifty day simple moving average is $579.44 and its two-hundred day simple moving average is $564.03. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $935.86.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, beating analysts’ consensus estimates of $9.73 by $2.10. The business had revenue of $3.75 billion for the quarter, compared to analysts’ expectations of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The business’s quarterly revenue was up .9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $12.46 earnings per share. As a group, analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, December 5th. Shareholders of record on Thursday, November 20th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Thursday, November 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is 8.43%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.